These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31778208)

  • 1. Effect of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers among women with thrombophilia or previous venous thromboembolism.
    Braga GC; Brito MB; Ferriani RA; Oliveira LC; Garcia AA; Pintão MC; Vieira CS
    Int J Gynaecol Obstet; 2020 Mar; 148(3):381-385. PubMed ID: 31778208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral anticoagulant therapy does not modify the bleeding pattern associated with the levonorgestrel-releasing intrauterine system in women with thrombophilia and/or a history of thrombosis.
    Braga GC; Brito MB; Ferriani RA; Oliveira LC; Garcia AA; Pintão MC; Vieira CS
    Contraception; 2014 Jan; 89(1):48-53. PubMed ID: 24183329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
    Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
    Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of the levonorgestrel-releasing intrauterine system position on bleeding patterns in reproductive age women.
    Alves RDMS; Rabelo MM; Andrade VR; Cabral RCS; Merriman JW; Brito MB
    Int J Gynaecol Obstet; 2019 Dec; 147(3):326-331. PubMed ID: 31489621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS).
    Selim MF; Hussein AF
    Contraception; 2013 Apr; 87(4):396-403. PubMed ID: 23332246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.
    Gemzell-Danielsson K; Apter D; Hauck B; Schmelter T; Rybowski S; Rosen K; Nelson A
    PLoS One; 2015; 10(9):e0135309. PubMed ID: 26378938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome: Metabolic and Clinical Effects.
    da Silva AV; de Melo AS; Barboza RP; de Paula Martins W; Ferriani RA; Vieira CS
    Reprod Sci; 2016 Jul; 23(7):877-84. PubMed ID: 26733500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy.
    Graner S; Mc Taggart J; Nordström F; Melander E; Widenberg J; Kopp Kallner H
    Acta Obstet Gynecol Scand; 2019 Jul; 98(7):937-943. PubMed ID: 30737766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.
    Bahamondes MV; Monteiro I; Castro S; Espejo-Arce X; Bahamondes L
    Hum Reprod; 2010 May; 25(5):1158-64. PubMed ID: 20185512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk markers among obese women using the levonorgestrel-releasing intrauterine system: A randomised controlled trial.
    Zueff LFN; Melo AS; Vieira CS; Martins WP; Ferriani RA
    Obes Res Clin Pract; 2017; 11(6):687-693. PubMed ID: 28693985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of a 52-mg levonorgestrel-releasing intrauterine system in women with cardiovascular disease.
    Ueda Y; Kamiya CA; Horiuchi C; Miyoshi T; Hazama R; Tsuritani M; Iwanaga N; Neki R; Ikeda T; Yoshimatsu J
    J Obstet Gynaecol Res; 2019 Feb; 45(2):382-388. PubMed ID: 30259601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
    Wildemeersch D; Janssens D; Andrade A
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis.
    Conz L; Mota BS; Bahamondes L; Teixeira Dória M; Françoise Mauricette Derchain S; Rieira R; Sarian LO
    Acta Obstet Gynecol Scand; 2020 Aug; 99(8):970-982. PubMed ID: 31990981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
    Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
    Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding pattern difference between levonorgestrel intrauterine system and copper intrauterine devices inserted immediately post-abortion: a multicenter, prospective, observational cohort study in Chinese women.
    Chen X; Li Q; Wang X; Chen J; Lv W; Shi B; Wang H; Luo J; Li J
    Curr Med Res Opin; 2018 May; 34(5):873-880. PubMed ID: 29298525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One year quality of life measured with SEC-QoL in levonorgestrel 52 mg IUS users.
    Cristobal I; Lete LI; Viuda E; Perulero N; Arbat A; Canals I
    Contraception; 2016 Apr; 93(4):367-371. PubMed ID: 26764120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception.
    Mansour D
    Contraception; 2012 Mar; 85(3):224-34. PubMed ID: 22067761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use.
    Gemzell-Danielsson K; Apter D; Dermout S; Faustmann T; Rosen K; Schmelter T; Merz M; Nelson A
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():22-28. PubMed ID: 27930941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system.
    Seeber B; Ziehr SC; Gschlieβer A; Moser C; Mattle V; Seger C; Griesmacher A; Concin N; Concin H; Wildt L
    Contraception; 2012 Oct; 86(4):345-9. PubMed ID: 22402256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.